

1481/65019-DA-PCT-US/JPW/AJM/CY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann and Ravinder N. Maini
Serial No. : 09/754,004 Examiner: P. Gambel
Filed : January 3, 2001 Group Art Unit: 1644
For : TNF α ANTAGONISTS AND METHOTREXATE IN THE
TREATMENT OF TNF-MEDIATED DISEASE

1185 Avenue of the Americas
New York, New York 10036
December 3, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mail Stop RCE

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (**EXHIBIT A**). Copies of the disclosures listed below as items 1 and 2 are attached hereto as **EXHIBITS 1 and 2**.

1. Cronstein, et al., "Therapeutic Cocktails for Rheumatoid Arthritis: The Mixmaster's Guide", Arthritis & Rheumatism, 50(7):2041-2043 (2004) (**EXHIBIT 1**), and
2. Genovese, et al., "Combination Therapy with Etanercept and Anakinra in the Treatment of Patients with Rheumatoid Arthritis Failing


Applicants: Marc Feldmann and Ravinder N. Maini
Serial No.: 09/754,004
Filed: January 3, 2001
Page 2

Methotrexate", Arthritis & Rheumatism,
50(5):1412-1419 (2004) (**EXHIBIT 2**).


If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorneys invite the Examiner to telephone them at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if a fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	09/754,004
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Filing Date	January 3, 2001
				First Named Inventor	Marc Feldmann, et al.
				Art Unit	1644
				Examiner Name	P. Gambel
				Attorney Docket No.	1455/65019-DA-PCT-US/JPW/AJM/CY
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials[*]	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²
	1	CRONSTEIN, et al., "Therapeutic Cocktails for Rheumatoid Arthritis: The Mixmaster's Guide", <u>Arthritis & Rheumatism</u> , 50(7):2041-2043 (2004); and			
	2	GENOVESE, et al., "Combination Therapy with Etanercept and Anakinra in the Treatment of Patients with Rheumatoid Arthritis Failing Methotrexate", <u>Arthritis & Rheumatism</u> , 50(5):1412-1419 (2004).			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.</small></p>					